Skip to main content

Summary

for people ages 2–22 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

This is a 5-part, open-label, Phase 1/1b multicenter, dose escalation study in pediatric patients with relapsed refractory solid tumors; 2) primary CNS tumors; 3) neuroblastoma; 4) non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1 or ALK gene rearrangements; and 5) patients who are otherwise eligible but unable to swallow capsules. The study is designed to explore the safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetics, and antitumor activity of entrectinib.

Official Title

A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Keywords

Solid Tumors CNS Tumors Neuroblastoma TRK Tyrosine kinase NTRK NTRK1 NTRK2 NTRK3 ROS1 ALK Pediatric Relapsed Refractory Solid Tumor Metastatic Cancer Gene rearrangement Infantile fibrosarcoma Secretory breast cancer Congenital mesoblastic nephroma Pontine glioma Brain tumors Sarcoma Ewing sarcoma Glial tumors Salivary Gland Cancer (MASC) Papillary thyroid cancer Medulloblastoma Wilms tumor (anaplastic) Neoplasms Central Nervous System Neoplasms

Eligibility

You can join if…

Open to people ages 2–22

  1. Ability to swallow capsules unless enrolled in Part E
  2. Body surface area (BSA): Subjects must have a body surface area ≥ 0.45 m2 at the time of the study enrollment, unless enrolled in Part E
  3. Disease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ±Curie Scale Criteria or RANO/RANO-BM
  4. Tumor type:
  5. Part A: Relapsed or refractory extracranial solid tumors and (Phase 1b expansion)relapsed or refractory extracranial solid tumors with molecular alterations,non-gene fusions;
  6. Part B: Relapsed or refractory primary CNS tumors with molecular alterations,including gene fusions, documented by a CLIA-approved lab prior to enrollment;
  7. Part C: Relapsed or refractory neuroblastoma;
  8. Part D: Relapsed or refractory non-neuroblastoma, extracranial solid tumors with NTRK1/2/3, ROS1, or ALK gene fusions documented by a CLIA-approved lab prior to enrollment;
  9. Part E: Any patient unable to swallow capsules who otherwise meet all other eligibility criteria for Part A (expansion) B, C or D
  10. Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
  11. Archival tumor tissue from diagnosis or, preferably, at relapse
  12. Age: Male or female age ≥ 2 years and < 22 years unless enrolled in Part E
  13. Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
  14. Patient's cancer must have relapsed after or failed to respond to frontline curative therapy or there must not be other potentially curative treatment options available
  15. . Adequate organ and neurologic function
  16. . Females of child bearing potential must have a negative serum pregnancy test within 14 days prior to entrectinib dosing

You CAN'T join if...

  1. Receiving other experimental therapy
  2. Known congenital long QT syndrome
  3. Known active infections
  4. Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
  5. Incomplete recovery from acute effects of any surgery prior to treatment.
  6. Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
  7. Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.

Locations

  • UCSF Benihoff Children's accepting new patients
    San Francisco, California, 94143, United States
  • UCSD Rady Children's Hospital accepting new patients
    San Diego, California, 92123, United States
  • Univ of Utah, Primary Children's Hospital not yet accepting patients
    Salt Lake City, Utah, 84113, United States
  • Oregon Health Science University not yet accepting patients
    Portland, Oregon, 97239, United States
  • Children's Hospital Colorado accepting new patients
    Aurora, Colorado, 80045, United States
  • Cook Children's Hospital not yet accepting patients
    Fort Worth, Texas, 76104, United States
  • Texas Children's Cancer, Baylor College of Medicine accepting new patients
    Houston, Texas, 77030, United States
  • Univ of Minnesota Medical Center not yet accepting patients
    Minneapolis, Minnesota, 55454, United States
  • Washington Univ School of Medicine accepting new patients
    Saint Louis, Missouri, 63110, United States
  • St. Jude Children's Research Hospital not yet accepting patients
    Memphis, Tennessee, 38105, United States
  • Univ of Chicago Medical Center accepting new patients
    Chicago, Illinois, 60615, United States
  • Cincinnati Children's Hospital not yet accepting patients
    Cincinnati, Ohio, 45229, United States
  • Nationwide Children's Hospital not yet accepting patients
    Columbus, Ohio, 43205, United States
  • Children's Healthcare of Atlanta accepting new patients
    Atlanta, Georgia, 30322, United States
  • Children's Hospital of Philadelphia accepting new patients
    Philadelphia, Pennsylvania, 19104, United States
  • Columbia Univ Ped Hem/Onc accepting new patients
    New York, New York, 10032, United States
  • Memorial Sloan Kettering accepting new patients
    New York, New York, 10065, United States
  • Dana Farber Cancer Institute accepting new patients
    Boston, Massachusetts, 02215, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ignyta, Inc.
ID
NCT02650401
Phase
Phase 1
Lead Scientist
Amit Sabnis
Study Type
Interventional
Last Updated
June 23, 2017
I’m interested in this study!